Promising Phase II Data For New Alzheimer's Disease Drug Presented

A novel drug (ORM-12741) developed by Orion Corporation could improve cognitive and behavioral symptoms in patients with Alzheimer's disease. According to a Phase IIa study, presented yesterday at American Academy of Neurology's Annual Meeting in San Diego, ORM-12741 (a potent and selective alpha-2c adrenoceptor  antagonist  ) showed significant positive effects on episodic memory in patients with moderate Alzheimer's disease.

No comments:

Post a Comment